|
|
|
|
|
|
|
|
|
|
| Email |
ckahan-radhuber@srinstitute.com
|
|
| Category |
Science: Chemistry
|
|
|
|
|
|
|
|
|
|
|
|
| Description |
AN EMERGING TARGET FAMILY WITH CROSS THERAPEUTIC APPLICATIONS
PRESENTATIONS BY:
Arqule Inc.
Bayer Corporation
Bristol-Myers Squibb
Cornell University
Eli Lilly & Company
Gene Networks Inc.
GlaxoSmithKline Research & Development
Karo Bio
Maxia Pharmaceuticals
National Cancer Institute
NICHD/NIH
NYU School of Medicine
Panvera Corporation
Pfizer Global R & D - La Jolla Labs
Structural GenomiX
Wyeth Pharmaceuticals
X-Ceptor Therapeutics
ORGANIZED INTO THREE SECTIONS:
1 - NUCLEAR RECEPTOR SIGNALING MECHANISMS
2 - METHODS FOR MEASURING NUCLEAR RECEPTOR ACTIVITIES
3 - DRUG DISCOVERY APPROACHES FOR SPECIFIC NUCLEAR RECEPTOR TARGET CLASSES
HIGHLIGHTS INCLUDE:
A Real Time Sensing Assay for Nuclear Receptor Ligands
NATIONAL CANCER INSTITUTE
Rational Development of Novel Nuclear Hormone Receptor Antagonists Through in silico Modeling Techniques
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Mechanisms Underlying Selective Coactivator Recognition by Nuclear Receptors
LILLY RESEARCH LABORATORIES
Measurement Of Ligand-Induced Conformational Changes In Nuclear Hormone Receptors Using Peptides From Phage Display Libraries
KARO BIO USA
The Peroxisome Proliferator-Activated Receptors: StructurEs and Drug Discovery
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT
|
|
|
|
